arrow
K

Ken A. Olaussen

inserm and gustave roussy and université paris-saclay
H指数:35
被引数:5,963

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib

ALK K1150dup突变介导对一线lorlatinib的耐药性并保留对gilteritinib的敏感性

2026-05-130
OAAI
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

破译癌症的耐药机制: MATCH-R研究的最终报告,重点是分子驱动和PDX的发展

2024-10-040
OAAI
Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer

FGFR驱动的尿路上皮癌对选择性FGFR抑制剂的耐药性

2023-06-2825
OAAI
Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
2023-04-040
PRE
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

在Gustave Roussy进行的MATCH-R重复活检试验的可行性和首次报告

2020-09-0821
OAAI
Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches
2020-08-150
PRE
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer

BRAFV600E非小细胞肺癌对BRAF和MEK抑制剂耐药的分子机制

2020-06-0166
OAAI
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

ALK重排肺癌对第三代ALK抑制剂洛拉替尼的不同耐药机制

2020-01-03119
OAAI
Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer
2019-07-010
PRE
Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study
2019-07-011
PRE